Biotron Ltd Investor Webinar Transcript
(audio in progress) Statements. So I think just to -- for people who may not be familiar with Biotron or certainly with our updated story, at the end of last year, Biotron, which had primarily been an antiviral company for a number of years, expanded its drug portfolio with the acquisition of Sedarex Limited. Sedarex was a public unlisted company that has next-generation general anesthetic that's late stage, as well as other potential indications in the neurocognitive, neuroscientific space.
And we liked the Sedarex story, we liked the Sedarex technology, and believed that the general anesthetic in particular provides potential fast, low-risk path to commercialization with access and exposure to a very large global marketplace.
I should say that Biotron's antivirals, the work on that is continuing. I'll mention HIV along the way, but we're really focusing right now on hepatitis B, and people may have seen the announcement that we put out yesterday with some updated data, and I'll talk about hep
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
